AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28013123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin 40 IU taken four times a day (QID)
Number of subjects: 35
Study 28013123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 26174460 — intervention group
Group type: EXPERIMENTAL
Intervention: Avena sativa lotion, twice a day for 2 weeks
Number of subjects: 23
Study 26174460 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted vinegar, for 2 weeks
Number of subjects: 23
Study 26174460 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine tablets, for 2 weeks
Number of subjects: 23
Study 23233371 — intervention group
Group type: EXPERIMENTAL
Intervention: ExPeak‐Reg
Number of subjects: 531
Study 23233371 — intervention group
Group type: EXPERIMENTAL
Intervention: ExRec‐Reg
Number of subjects: 531
Study 23233371 — intervention group
Group type: COMPARATOR
Intervention: Rest‐Reg
Number of subjects: 531
Study 21626403 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-septum lead placement
Number of subjects: 286
Study 21626403 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apex lead placement
Number of subjects: 286
Study 18562464 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - School-based programme (16 sessions in 3 years)
Number of subjects: 1952
Study 18562464 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No intervention
Number of subjects: 1952
Study 16866675 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheter
Number of subjects: 75
Study 16866675 — intervention group
Group type: COMPARATOR
Intervention: Condom catheter
Number of subjects: 75
Study 12964648 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received antimicrobial treatment (topical application of NaF and iodine solution) and restorative care using glass ionomer cement.
Number of subjects: 81
Study 12964648 — intervention group
Group type: COMPARATOR
Intervention: Control group received primary care intervention and oral hygiene kits.
Number of subjects: 81
Study 12964648 — intervention group
Group type: COMPARATOR
Intervention: Both groups received primary care intervention and oral hygiene kits.
Number of subjects: 81
Study 12964648 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal caries increase was a significant factor influencing the caries experience of the children.
Number of subjects: 81
Study 11518470 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin-glue coated collagen patch
Number of subjects: 60
Study 11518470 — intervention group
Group type: COMPARATOR
Intervention: Standard closure
Number of subjects: 60
Study 9401830 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 400 mg retard AWD (test)
Number of subjects: 18
Study 8269790 — intervention group
Group type: COMPARATOR
Intervention: Usual Care group intervention
Number of subjects: 6000
Study 2851386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (B) 0.3 gm/kg body weight
Number of subjects: 65
Study 2851386 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 65
Study 2851386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (B)
Number of subjects: 65
Study 30082118 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization (in patients with pulse pressure < 60 mmHg)
Number of subjects: 2294
Study 30082118 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (in patients with pulse pressure < 60 mmHg)
Number of subjects: 2294
Study 30082118 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization (in patients with pulse pressure ≥ 60 mmHg)
Number of subjects: 2294
Study 30082118 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (in patients with pulse pressure ≥ 60 mmHg)
Number of subjects: 2294
Study 30082118 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2294
Study 27813395 — intervention group
Group type: EXPERIMENTAL
Intervention: Precise liver resection using simplified blocking combined with electrotome (Group A)
Number of subjects: 61
Study 27813395 — intervention group
Group type: COMPARATOR
Intervention: Precise liver resection using half‐hepatic occlusion + CUSA assisting liver parenchyma transection + lower central venous pressure (Group B)
Number of subjects: 61
Study 27813395 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 61
Study 27813395 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 61
Study 24547757 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery-oriented assessment
Number of subjects: 192
Study 24547757 — intervention group
Group type: COMPARATOR
Intervention: Performance-oriented assessment
Number of subjects: 192
Study 24547757 — intervention group
Group type: COMPARATOR
Intervention: No assessment
Number of subjects: 192
Study 22734586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) at a fixed dose of 10 mg/kg/day for 18 months
Number of subjects: 60
Study 22734586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20371785 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate therapy for 6 months (group 1, n = 183)
Number of subjects: 364
Study 20371785 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate therapy for 12 months (group 2, n = 181)
Number of subjects: 364
Study 20371785 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate therapy for 6 months (group 1)
Number of subjects: 364
Study 20371785 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate therapy for 12 months (group 2)
Number of subjects: 364
Study 20371785 — intervention group
Group type: EXPERIMENTAL
Intervention: MRP8/14 levels during remission
Number of subjects: 364
Study 17325227 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosmidomycin‐clindamycin therapy given every 12 h for 3 days
Number of subjects: 105
Study 17325227 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine (single oral dose)
Number of subjects: 105
Study 15685261 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual comprehensive preventative health evaluation (CPHE)
Number of subjects: 853
Study 12149659 — intervention group
Group type: EXPERIMENTAL
Intervention: Efonidipine
Number of subjects: 0
Study 12149659 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not treated with efonidipine)
Number of subjects: 0
Study 9539595 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective group (R and MC nerves blocked with 10 mL of 2% lidocaine each; M and U nerves blocked with 10 mL of 0.5% bupivacaine each)
Number of subjects: 34
Study 9539595 — intervention group
Group type: COMPARATOR
Intervention: Control group (each of the four nerves infiltrated with 10 mL of a mixture of 2% lidocaine and 0.5% bupivacaine)
Number of subjects: 34
Study 9539595 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 7530868 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 0
Study 7530868 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 0
Study 2792786 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise training (PET)
Number of subjects: 14
Study 2792786 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control (NEC)
Number of subjects: 14
Study 378626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg bid
Number of subjects: 40
Study 378626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30945504 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal heat-type acupuncture needle therapy (IHTAN), 42 ℃, 20 min, once a week for 4 weeks
Number of subjects: 96
Study 30945504 — intervention group
Group type: COMPARATOR
Intervention: Warm needle moxibustion therapy, once every other day for 4 weeks
Number of subjects: 96
Study 30945504 — intervention group
Group type: EXPERIMENTAL
Intervention: IHTAN
Number of subjects: 96
Study 30945504 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 28917230 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg green coffee bean extract for 8 weeks
Number of subjects: 64
Study 28917230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 25817296 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (R) plus cyclophosphamide, vincristine and prednisone
Number of subjects: 428
Study 25817296 — intervention group
Group type: EXPERIMENTAL
Intervention: R plus cyclophosphamide, doxorubicin, vincristine and prednisone
Number of subjects: 428
Study 25817296 — intervention group
Group type: EXPERIMENTAL
Intervention: R plus mitoxantrone and fludarabine
Number of subjects: 428
Study 23924205 — intervention group
Group type: EXPERIMENTAL
Intervention: Short transverse (ST) incision
Number of subjects: 66
Study 23924205 — intervention group
Group type: COMPARATOR
Intervention: Hockey-stick (HS) incision
Number of subjects: 66
Study 20825915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax AWS videolaryngoscope (PAV)
Number of subjects: 0
Study 20825915 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MAC)
Number of subjects: 0
Study 20003351 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-bedding group
Number of subjects: 128
Study 20003351 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 128
Study 17046017 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory involvement in arithmetic strategy selection and efficiency
Number of subjects: 0
Study 17046017 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual differences (processing speed, arithmetic skill, gender, math anxiety)
Number of subjects: 0
Study 17046017 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term memory capacity
Number of subjects: 0
Study 16391244 — intervention group
Group type: EXPERIMENTAL
Intervention: Short arm cast
Number of subjects: 113
Study 16391244 — intervention group
Group type: COMPARATOR
Intervention: Long arm cast
Number of subjects: 113
Study 14661011 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 112
Study 14661011 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 112
Study 10348277 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group program
Number of subjects: 32
Study 10348277 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (written information and brief counseling)
Number of subjects: 32
Study 8747271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicle screw fixation
Number of subjects: 0
Study 1673495 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 (40 mg by mouth)
Number of subjects: 10
Study 1673495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7047329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and intrathecal immunoglobulin (Ig) therapy: 10 g Ig as a short infusion on two consecutive days, plus 500 mg by intrathecal injection every second day for bacterial infections and every fifth day for viral infections.
Number of subjects: 68
Study 7047329 — intervention group
Group type: COMPARATOR
Intervention: Control group received usual therapy only, principally antibiotics for purulent meningitis.
Number of subjects: 68
Study 31631409 — intervention group
Group type: EXPERIMENTAL
Intervention: FatSegNet (automated deep learning pipeline)
Number of subjects: 0
Study 31237459 — intervention group
Group type: EXPERIMENTAL
Intervention: Values and Options in Cancer Care intervention
Number of subjects: 0
Study 31237459 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 28514807 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, 20 min)
Number of subjects: 13
Study 28514807 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 13
Study 24622414 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (15 mg intramuscularly per week for two 12-week courses, separated by a 12-week pause)
Number of subjects: 49
Study 24622414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 24622414 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 49
Study 21703824 — intervention group
Group type: EXPERIMENTAL
Intervention: HI-NEG patients
Number of subjects: 59
Study 21703824 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW-NEG patients
Number of subjects: 59
Study 21703824 — intervention group
Group type: COMPARATOR
Intervention: CN patients
Number of subjects: 59
Study 21703824 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher self-reported trait negative affect
Number of subjects: 59
Study 18813407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg (group K)
Number of subjects: 120
Study 18813407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 0.5 mg/kg (group P)
Number of subjects: 120
Study 18813407 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group S)
Number of subjects: 120
Study 17217869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 0
Study 17217869 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 0
Study 17217869 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 17217869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergotamine
Number of subjects: 0
Study 17217869 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0
Study 12781852 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg/d folic acid supplement
Number of subjects: 78
Study 12781852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 10692621 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lidocaine (2 mg/kg bolus followed by 2 mg kg(‐1)h(‐1) infusion)
Number of subjects: 12
Study 10692621 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional lidocaine (40 ml lidocaine, 0.05%)
Number of subjects: 12
Study 10692621 — intervention group
Group type: COMPARATOR
Intervention: Control (40 ml NaCl, 0.9%)
Number of subjects: 12
Study 9459116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous polyvalent immunoglobulins (IVIG) at a dose of 1 g/kg for 3 days
Number of subjects: 41
Study 9459116 — intervention group
Group type: COMPARATOR
Intervention: Control group (ICU patients not receiving IVIG)
Number of subjects: 41
Study 9459116 — intervention group
Group type: COMPARATOR
Intervention: Non-ICU, noninfected patients
Number of subjects: 41
Study 1585493 — intervention group
Group type: EXPERIMENTAL
Intervention: Euro-Collins (EC) in situ flush
Number of subjects: 56
Study 1585493 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin (UW) in situ flush
Number of subjects: 56
Study 1585493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EC and UW solutions
Number of subjects: 56
Study 3001233 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 17
Study 29618436 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta
Number of subjects: 150
Study 29618436 — intervention group
Group type: COMPARATOR
Intervention: Curosurf
Number of subjects: 150
Study 26509765 — intervention group
Group type: EXPERIMENTAL
Intervention: i‐gel (laryngeal mask)
Number of subjects: 110
Study 26509765 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube
Number of subjects: 110
Study 24622832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (2 x 500 mg/day) and Essentiale forte (3 x 1 tablet/day) for 14 months
Number of subjects: 74
Study 24622832 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 x 5 mg/day) and Essentiale forte (3 x 1 tablet/day) for 14 months
Number of subjects: 74
Study 24622832 — intervention group
Group type: COMPARATOR
Intervention: Essentiale forte only for 14 months
Number of subjects: 74
Study 24622832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan and melatonin (groups I and II)
Number of subjects: 74
Study 24622832 — intervention group
Group type: COMPARATOR
Intervention: Essentiale forte only (group III)
Number of subjects: 74
Study 24245493 — intervention group
Group type: COMPARATOR
Intervention: Online after-care program, conducted once per week for eight weeks.
Number of subjects: 0
Study 20435245 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of tramadol 100 mg
Number of subjects: 26
Study 20435245 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of tramadol 100 mg
Number of subjects: 26
Study 20435245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 26
Study 19014839 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of lamotrigine (100 mg)
Number of subjects: 24
Study 19014839 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of lamotrigine (100 mg)
Number of subjects: 24
Study 16650416 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate challenge test (CCCT)
Number of subjects: 110
Study 16650416 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous FSH ovarian reserve test (EFORT)
Number of subjects: 110
Study 14675880 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 1.25 mg (increased to a maximum dose of 5 mg per day)
Number of subjects: 52
Study 14675880 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy with diuretic and ACE inhibitor)
Number of subjects: 52
Study 12434619 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% in-office hydrogen peroxide tooth-whitening touch-up agent
Number of subjects: 0
Study 10336103 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-focused maintenance program
Number of subjects: 67
Study 10336103 — intervention group
Group type: COMPARATOR
Intervention: Weight-focused maintenance program
Number of subjects: 67
Study 7863762 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA resurfacing
Number of subjects: 45
Study 7863762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricon stem
Number of subjects: 45
Study 7863762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricon-M prosthesis
Number of subjects: 45
Study 7863762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricon groups
Number of subjects: 45
Study 7863762 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable group (one third of patients)
Number of subjects: 45
Study 7863762 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable group (two thirds of patients)
Number of subjects: 45
Study 1828225 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic combined oral contraceptive (130 micrograms ethinylestradiol + 150 micrograms desorgestrel)
Number of subjects: 20
Study 1828225 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic combined oral contraceptive (30 micrograms ethinylestradiol + 50 micrograms levonorgestrel for 6 days, followed by 40 micrograms ethinylestradiol + 75 micrograms levonorgestrel for 5 days and 30 micrograms ethinylestradiol + 125 micrograms levonorgestrel for 10 days)
Number of subjects: 20
Study 6123122 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 or 10 mg mepindolol
Number of subjects: 104
Study 6123122 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mepindolol
Number of subjects: 104
Study 31292969 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tablets (LF 60 mg/d, LPO 7.8 mg/d)
Number of subjects: 150
Study 31292969 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tablets (LF 20 mg/d, LPO 2.6 mg/d)
Number of subjects: 150
Study 31292969 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 150
Study 27662341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene-rich tomato nutrient complex (TNC)
Number of subjects: 65
Study 27662341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein
Number of subjects: 65
Study 27662341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 27308645 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin and Fennel Essential Oil (CU-FEO)
Number of subjects: 121
Study 27308645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 24467256 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 34
Study 24467256 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 34
Study 22751469 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip-assisted tube placement
Number of subjects: 143
Study 22751469 — intervention group
Group type: COMPARATOR
Intervention: Standard tube placement
Number of subjects: 143
Study 19150955 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line combination therapy with capecitabine and irinotecan (specific dosage and duration not mentioned)
Number of subjects: 32
Study 17766316 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory stressor task
Number of subjects: 44
Study 17766316 — intervention group
Group type: COMPARATOR
Intervention: Control manipulation
Number of subjects: 44
Study 15076791 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (200 mg.wk(‐1), intramuscularly)
Number of subjects: 16
Study 15076791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12230027 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaving needle (LN) acupuncture stimulation
Number of subjects: 0
Study 12230027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparrow pecking method (SPM) acupuncture stimulation
Number of subjects: 0
Study 12230027 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (general)
Number of subjects: 0
Study 9847429 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray, 256 microgram
Number of subjects: 273
Study 9847429 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous suspension, 200 microgram
Number of subjects: 273
Study 9847429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 8021907 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40-120 mg)
Number of subjects: 30
Study 8021907 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80-200 mg)
Number of subjects: 30
Study 2640054 — intervention group
Group type: EXPERIMENTAL
Intervention: FDP 20 g
Number of subjects: 20
Study 2640054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20